Loading data for ACTU — first visit, this takes a few seconds.
Actuate Therapeutics Inc.... (ACTU)
NasdaqGM: ACTU
· Real-Time Price · USD
1.04
-0.01 (-0.95%)
At close: Aug 19, 2026, 11:10 AM
Actuate Therapeutics Inc. Common stock (ACTU) Stock Price, Analysis & Data
-0.95% (1D)
| Bid | 0.8 |
| Market Cap | 25.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.54M |
| Beta | n/a |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.45 |
| P/B (ttm) | 3.08 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 1.45 |
| Volume | 92,085 |
| Avg. Volume (20D) | 266,350 |
| Open | 1.04 |
| Previous Close | 1.05 |
| Day's Range | 1.00 - 1.10 |
| 52-Week Range | 0.90 - 9.22 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2024
Employees 12
Stock Exchange NasdaqGM
Ticker Symbol ACTU
Website https://actuatetherapeutics.com
Financial Performance
In 2025, Actuate Therapeutics Common stock's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -22.23M, a decrease of -18.54%.
Financial StatementsEarnings Surprise
Actuate Therapeutics Common stock has released their quarterly earnings on Aug 14, 2026:
Actuate Therapeutics Inc. Common stock is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2